Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00736749
First received: August 15, 2008
Last updated: April 7, 2011
Last verified: April 2011
  Purpose

RATIONALE: Developing a way to track patients enrolled in Children's Oncology Group studies will help doctors gather long-term follow-up information and may help the study of cancer in the future.

PURPOSE: This clinical trial is studying long-term follow-up in patients who are or have participated in Children's Oncology Group studies.


Condition Intervention
Brain and Central Nervous System Tumors
Chronic Myeloproliferative Disorders
Leukemia
Long-term Effects Secondary to Cancer Therapy in Children
Lymphoma
Lymphoproliferative Disorder
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Precancerous Condition
Unspecified Childhood Solid Tumor, Protocol Specific
Other: survey administration
Procedure: assessment of therapy complications
Procedure: long-term screening
Procedure: study of high risk factors

Study Type: Observational
Official Title: Umbrella Long-Term Follow-Up Protocol

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Development of mechanism for tracking and retaining patients enrolled on COG protocols [ Designated as safety issue: No ]
  • Maintenance of regular, lifetime contact with patients [ Designated as safety issue: No ]
  • Location of targeted patients lost to follow up [ Designated as safety issue: No ]
  • Current patient contact information and reported health status updates [ Designated as safety issue: No ]
  • Collection of protocol-specific outcome data [ Designated as safety issue: No ]
  • Collection of cumulative therapeutic exposure data [ Designated as safety issue: No ]

Estimated Enrollment: 906
Study Start Date: May 2007
Estimated Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To develop a mechanism for tracking and retaining patients enrolled on COG protocols.
  • To maintain regular, lifetime contact with patients in order to obtain current identification and contact information, and self/parent-reported health status.
  • To locate patients who are lost-to-follow-up for COG (or Legacy Group) protocols targeted for follow-up by the Long-Term Follow-Up Center (LTFC).
  • To provide current patient contact information and self/parent-reported health status updates to the COG Statistics and Data Center (SDC) and to each patient's COG institution.
  • To facilitate collection of protocol-specific outcome data through collaboration with the COG Late Effects Committee, the SDC, and the member institutions.
  • To collect cumulative therapeutic exposure data (via therapeutic summaries completed online by treating institutions) on patients completing active therapy.

OUTLINE: This is an umbrella protocol for all long-term follow-up at COG institutions. Approximately 6 months after completion of therapy patients receive a mailed packet introducing the Long-Term Follow-Up Center (LTFC) and containing information related to their individualized, protocol-specific follow-up guidelines. Patients are asked to complete a patient response form, verify information provided in packet, update contact information, and complete a Health Status Update Form. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients receive protocol-specific automatic reminders, and may respond by use of postage prepaid envelopes, email, or 24-hour toll-free telephone.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Must be newly diagnosed with a primary malignancy and enrolled on a frontline COG therapeutic trial for treatment of a primary malignancy OR must have been enrolled on a COG (or Legacy Group) therapeutic or non-therapeutic trial calling for long-term follow-up, including any of the following:

    • Hodgkin lymphoma

      • CCG-5942
      • POG-9425
      • POG-9426
      • COG-AHOD0031
    • Brain tumor

      • CCG-A9961
    • Acute lymphoblastic leukemia

      • COG-ALTE02C2
    • Neuroblastoma

      • COG-A3973
    • Rhabdomyosarcoma

      • IRS-III
      • IRS-IV-Stage 1
      • IRS-IV-Stage 2/3
      • IRS-IV-Stage/Group 4
  • Must reside in the U.S. during trial enrollment

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00736749

  Show 113 Study Locations
Sponsors and Collaborators
Children's Oncology Group
Investigators
Study Chair: Smita Bhatia, MD, MPH Beckman Research Institute
Investigator: Dennis Deapen, DrPH USC/Norris Comprehensive Cancer Center
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00736749     History of Changes
Other Study ID Numbers: CDR0000590123, COG-ALTE05N1
Study First Received: August 15, 2008
Last Updated: April 7, 2011
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
long-term effects secondary to cancer therapy in children
acute myeloid leukemia/transient myeloproliferative disorder
unspecified childhood solid tumor, protocol specific
accelerated phase chronic myelogenous leukemia
acute undifferentiated leukemia
atypical chronic myeloid leukemia, BCR-ABL negative
blastic phase chronic myelogenous leukemia
childhood acute lymphoblastic leukemia in remission
childhood acute myeloid leukemia in remission
childhood chronic myelogenous leukemia
chronic myelomonocytic leukemia
chronic phase chronic myelogenous leukemia
juvenile myelomonocytic leukemia
mast cell leukemia
meningeal chronic myelogenous leukemia
progressive hairy cell leukemia, initial treatment
prolymphocytic leukemia
secondary acute myeloid leukemia
stage 0 chronic lymphocytic leukemia
stage I chronic lymphocytic leukemia
stage II chronic lymphocytic leukemia
stage III chronic lymphocytic leukemia
stage IV chronic lymphocytic leukemia
T-cell large granular lymphocyte leukemia
untreated childhood acute lymphoblastic leukemia
untreated childhood acute myeloid leukemia and other myeloid malignancies
untreated hairy cell leukemia
stage I childhood Hodgkin lymphoma
stage II childhood Hodgkin lymphoma
stage III childhood Hodgkin lymphoma

Additional relevant MeSH terms:
Neoplasms
Leukemia
Lymphoma
Lymphoproliferative Disorders
Multiple Myeloma
Neoplasms, Plasma Cell
Plasmacytoma
Myelodysplastic Syndromes
Preleukemia
Myeloproliferative Disorders
Nervous System Neoplasms
Precancerous Conditions
Lymphoma, Non-Hodgkin
Central Nervous System Neoplasms
Lymphoma, Large-Cell, Anaplastic
Myelodysplastic-Myeloproliferative Diseases
Neoplasms by Histologic Type
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Bone Marrow Diseases
Neoplasms by Site
Nervous System Diseases

ClinicalTrials.gov processed this record on May 23, 2013